# Clinical outcomes of emicizumab prophylaxis in hemophilia A with FVIII inhibitors

## Abstract

Emicizumab prophylaxis demonstrates substantial efficacy in reducing bleeding episodes in hemophilia A patients with FVIII inhibitors across diverse patient populations. Ten studies encompassing randomized trials, observational cohorts, and registry data show annualized bleeding rates ranging from 0.0 to 4.4 events per year on emicizumab, representing 79-99% reductions compared to previous bypassing agent prophylaxis or episodic treatment. Between 63-88% of patients achieved zero treated bleeding episodes, with particularly marked improvements in joint bleeding. Standard dosing consists of 3 mg/kg weekly for 4 weeks followed by 1.5 mg/kg weekly maintenance, though weekly and every-2-week regimens show comparable efficacy. Safety is favorable, with injection site reactions being most common (3.6-15% incidence) and thrombotic events rare but serious, particularly when combined with high-dose activated prothrombin complex concentrate. Antidrug antibodies developed in 2 of 88 pediatric patients, with one experiencing loss of efficacy. Quality of life improved significantly across multiple domains including physical health, daily functioning, and school attendance. These outcomes appear consistent across age groups from infants to elderly adults and are maintained over follow-up periods extending to 42 months.

## Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question. More on methods

Records from Elicit search

- n = 200
- Papers screened using: Population, Intervention, Clinical Outcomes, Study Design, Data Extractability, Study Type, Publication Type, Study Duration
- n = 200
- Papers screened out
- n = 190
- Papers included for extraction
- n = 10

## Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of [Semantic Scholar](https://www.semanticscholar.org/) and [OpenAlex](https://openalex.org/).

We ran this query: “Clinical outcomes of emicizumab prophylaxis in hemophilia A with FVIII inhibitors”

The search returned 200 total results from Elicit.

We retrieved 200 papers most relevant to the query for screening.

## Screening

We screened in sources based on their abstracts that met these criteria:

- **Population**: Does the study include patients diagnosed with hemophilia A with confirmed FVIII inhibitors?
- **Intervention**: Does the study involve emicizumab administered as prophylactic therapy?
- **Clinical Outcomes**: Does the study report clinical outcomes related to bleeding, safety, quality of life, or treatment effectiveness?
- **Study Design**: Is the study design a randomized controlled trial, non-randomized controlled trial, cohort study, case series with ≥5 patients, systematic review, or meta-analysis?
- **Data Extractability**: Can clinical outcomes be separately identified for hemophilia A patients with inhibitors in this study?
- **Study Type**: Is this a human clinical study that reports clinical outcomes (not solely in vitro, animal studies, or purely pharmacokinetic/pharmacodynamic studies)?
- **Publication Type**: Is this a peer-reviewed study with original data (not a conference abstract, editorial, letter, or commentary without original data)?
- **Study Duration**: For prospective studies, does the follow-up period meet or exceed 12 weeks? (Answer “Yes” if this is a retrospective study or systematic review/meta-analysis)

We considered all screening questions together and made a holistic judgement about whether to screen in each paper.

## Data extraction

We asked a large language model to extract each data column below from each paper. We gave the model the extraction instructions shown below for each column.

- **Study Design**:
    - Extract study design and basic study characteristics, including:
        - Study type (RCT, observational, registry, etc.)
        - Single center vs multicenter
        - Sample size of hemophilia A patients with FVIII inhibitors specifically
        - Study objectives related to emicizumab outcomes

- **Patient Characteristics**:
    - Extract characteristics of hemophilia A patients with FVIII inhibitors enrolled in the study, including:
        - Age distribution (pediatric vs adult, specific age ranges)
        - Hemophilia A severity (mild, moderate, severe)
        - FVIII inhibitor status (high vs low responding, current inhibitor levels)
        - Previous inhibitor history (ITI status, failed ITI, etc.)
        - Baseline joint damage or other complications

- **Emicizumab Dosing**:
    - Extract all details about emicizumab prophylaxis regimen used in hemophilia A patients with inhibitors, including:
        - Loading dose schedule (if applicable)
        - Maintenance dose amount (mg/kg)
        - Dosing frequency (weekly, every 2 weeks, every 4 weeks)
        - Route of administration
        - Any dose adjustments or modifications during study

- **Previous Treatment**:
    - Extract details about treatments used before emicizumab in hemophilia A patients with inhibitors, including:
        - Type of bypassing agents used (rFVIIa, aPCC, etc.)
        - Dosing regimen of previous treatment (prophylactic vs on-demand)
        - Duration of previous treatment
        - Reason for switching to emicizumab
        - Any concurrent treatments allowed during emicizumab therapy

- **Efficacy Outcomes**:
    - Extract all bleeding-related efficacy outcomes for hemophilia A patients with inhibitors on emicizumab prophylaxis, including:
        - Annualized bleeding rate (ABR) for all bleeds and treated bleeds
        - Percentage of patients with zero treated bleeding episodes
        - Breakthrough bleeding episodes (number, severity, location)
        - Reduction in bleeding rate compared to previous treatment (if reported)
        - Joint bleeding rates specifically
        - Time to first bleeding episode

- **Safety Outcomes**:
    - Extract all safety and adverse event data for emicizumab use in hemophilia A patients with inhibitors, including:
        - Most frequent adverse events and their incidence rates
        - Serious adverse events related to emicizumab
        - Thrombotic events (arterial and venous)
        - Injection site reactions
        - Development of antidrug antibodies (ADAs) and neutralizing antibodies
        - Impact of ADAs on efficacy (loss of efficacy, breakthrough bleeding)
        - Treatment discontinuations due to adverse events

- **Quality of Life**:
    - Extract patient-reported outcomes and quality of life measures for hemophilia A patients with inhibitors receiving emicizumab, including:
        - Specific quality of life instruments used (HAL, HRQoL questionnaires)
        - Baseline and follow-up scores
        - Clinically meaningful changes in quality of life
        - Patient satisfaction with treatment
        - Impact on daily activities, work, or school attendance
        - Caregiver burden assessments (if applicable)

- **Follow-up Duration**:
    - Extract study timeline and follow-up information for emicizumab treatment in hemophilia A patients with inhibitors, including:
        - Total study duration
        - Median/mean follow-up time on emicizumab
        - Patient retention rates and reasons for discontinuation
        - Duration of efficacy and safety data collection
        - Long-term follow-up plans or extended studies mentioned

## Results

### Characteristics of included studies

The review included 10 studies evaluating emicizumab prophylaxis in hemophilia A patients with FVIII inhibitors, comprising randomized controlled trials, observational studies, registries, and systematic reviews.

| Study | Full text retrieved? | Study Type | Setting | Sample Size (inhibitor patients) | Median/Mean Follow-up | Patient Age | Hemophilia Severity |
|---|---|---|---|---|---|---|---|
| J. Oldenburg et al., 2017 | Yes | Randomized controlled trial | Multicenter | 109 | 24.0 weeks | Median 28 years (range 12-75) | Most severe |
| Sheikh Bilal Ahmad et al., 2025 | No | Retrospective observational | Single center | 17 | Not mentioned | Median 14 years | Severe |
| G. Young et al., 2019 | Yes | Phase 3 nonrandomized open-label | Multicenter | 85 | Median 57.6 weeks | <12 years (pediatric) | 97% severe |
| R. Muniz et al., 2023 | No | Systematic review and meta-analysis | N/A | Not mentioned | Not mentioned | Not mentioned | Not mentioned |
| M. Shima et al., 2016 | Yes | Open-label nonrandomized dose-escalation | Multicenter | At least 2 per cohort | 12 weeks | 12-59 years | Severe |
| Caroline Wall et al., 1971 | No | Observational registry | Multicenter | 117 | Median 42 months | Not mentioned | Not mentioned |
| G. Giuffrida et al., 2021 | No | Observational | Single center | 5 | Median 12 months | Median 26.8 years | Severe |
| Tiago Paiva Prudente et al., 2024 | No | Systematic review and meta-analysis | N/A | 56 | Not mentioned | Not mentioned | Not mentioned |
| M. Borhany et al., 2024 | Yes | Prospective observational | Single center | 19 | ~18 months | Mean 19.7 years | Severe |
| Sarina Levy-Mendelovich et al., 2023 | Yes | Prospective observational | Single center | 51 | Median 3.3 years | 1 month to 80 years | Not explicitly mentioned |

The studies varied substantially in design, ranging from large multicenter randomized trials to small single-center observational studies. Follow-up duration ranged from 12 weeks to a median of 42 months, with the longest individual follow-up extending to 3.3 years. Patient populations spanned all age groups, from pediatric patients under 12 years to adults up to 80 years. Most studies enrolled patients with severe hemophilia A.

Prior to emicizumab, patients were predominantly treated with bypassing agents including recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrate (aPCC), administered either episodically or prophylactically. The UK registry study included patients previously on immune tolerance induction (ITI), with varying ITI outcomes including successful ITI, failed ITI, and deferred ITI.

### Emicizumab dosing regimens

Emicizumab dosing varied across studies, with most employing a loading dose followed by maintenance therapy.

| Study | Loading Dose | Maintenance Dose | Frequency | Route |
|---|---|---|---|---|
| J. Oldenburg et al., 2017 | 3.0 mg/kg weekly for 4 weeks | 1.5 mg/kg | Weekly | Subcutaneous |
| Sheikh Bilal Ahmad et al., 2025 | Not mentioned | Not mentioned | Not mentioned | Not mentioned |
| G. Young et al., 2019 | 3 mg/kg weekly for 4 weeks | Group A: 1.5 mg/kg<br>Group B: 3 mg/kg<br>Group C: 6 mg/kg | Group A: Weekly<br>Group B: Every 2 weeks<br>Group C: Every 4 weeks | Subcutaneous |
| R. Muniz et al., 2023 | Not mentioned | Not mentioned | Not mentioned | Not mentioned |
| M. Shima et al., 2016 | Cohort 1: 1.0 mg/kg<br>Cohorts 2-3: 3.0 mg/kg | Cohort 1: 0.3 mg/kg<br>Cohorts 2-3: 1.0-3.0 mg/kg | Weekly | Subcutaneous |
| Caroline Wall et al., 1971 | Not mentioned | Not mentioned | Not mentioned | Not mentioned |
| G. Giuffrida et al., 2021 | 3 mg/kg weekly for 4 weeks | 1.5 mg/kg | Weekly or every 2 weeks | Subcutaneous |
| Tiago Paiva Prudente et al., 2024 | Not mentioned | Not mentioned | Not mentioned | Not mentioned |
| M. Borhany et al., 2024 | 3 mg/kg over first 4 weeks | 6 mg/kg/month | Monthly | Subcutaneous |
| Sarina Levy-Mendelovich et al., 2023 | Not mentioned | Not mentioned | Not mentioned | Not mentioned |

The most commonly reported regimen consisted of a loading dose of 3 mg/kg weekly for 4 weeks, followed by maintenance doses of 1.5 mg/kg weekly. The HAVEN 2 pediatric trial explored flexible dosing with weekly, every-2-week, and every-4-week maintenance regimens. All regimens were administered subcutaneously. One study allowed dose escalation to 3.0 mg/kg weekly for patients with suboptimal bleeding control.

### Effects on bleeding outcomes

Emicizumab prophylaxis demonstrated substantial reductions in bleeding across all studies reporting quantitative outcomes.

| Study | Annualized Bleeding Rate (ABR) on Emicizumab | ABR Before Emicizumab | Reduction | Zero Bleeds | Joint Bleeding |
|---|---|---|---|---|---|
| J. Oldenburg et al., 2017 | 2.9 events (95% CI 1.7-5.0) | 23.3 events (95% CI 12.3-43.9) no prophylaxis | 87% | 63% | Significant differences observed |
| Sheikh Bilal Ahmad et al., 2025 | 0.0 | 20.7 | 100% | Not mentioned | Significantly reduced |
| G. Young et al., 2019 | Group A: 0.3 (95% CI 0.17-0.50)<br>Group B: 0.2 (95% CI 0.03-1.72)<br>Group C: 2.2 (95% CI 0.69-6.81) | BPA prophylaxis (intraindividual) | 99% vs BPA prophylaxis | 77% (Group A) | Mean ABR in target joints decreased from 3.3 to 0 |
| R. Muniz et al., 2023 | Standard mean difference: -1.7 (95% CI -2.4 to -0.9) | N/A | N/A | Not mentioned | Not mentioned |
| M. Shima et al., 2016 | Cohort 1: 4.4<br>Cohort 2: 0.0<br>Cohort 3: 0.0 | Cohort 1: 32.5<br>Cohort 2: 18.3<br>Cohort 3: 15.2 | Significant reduction across cohorts | 73% | Cohort 1: 27.4 to 4.3<br>Cohort 2: 15.2 to 0.0<br>Cohort 3: 9.1 to 0.0 |
| Caroline Wall et al., 1971 | 0.32 (95% CI 0.18-0.39) | N/A | 89% reduction | 88% (increased from 45%) | Not mentioned |
| G. Giuffrida et al., 2021 | 0.4 | 1.8 | From 1.8 to 0.4 | Not mentioned | Not mentioned |
| Tiago Paiva Prudente et al., 2024 | Standard mean difference: -1.58 (95% CI -2.50 to -0.66) | N/A | N/A | Not mentioned | Not mentioned |
| M. Borhany et al., 2024 | 2.4% | 53.6% | From 53.6% to 2.4% | Not mentioned | >90% reduced to 2.4% |
| Sarina Levy-Mendelovich et al., 2023 | Decrease observed | N/A | Not specified | Not mentioned | Not mentioned |

The magnitude of bleeding reduction was remarkably consistent across studies. The HAVEN 1 trial demonstrated an 87% reduction in bleeding rate with emicizumab prophylaxis compared to no prophylaxis (2.9 vs 23.3 events per year). When compared to previous bypassing agent prophylaxis, reductions were even more pronounced: 79% lower in HAVEN 1 group C, 99% lower in the HAVEN 2 pediatric trial, and 89% lower in the UK registry study.

Zero bleeding episodes were achieved by 63% of patients in HAVEN 1, 77% in HAVEN 2 group A, 73% in the Shima dose-escalation study, and 88% in the UK registry (increased from 45% pre-emicizumab). The percentage achieving zero bleeds increased substantially when comparing pre- and post-emicizumab periods.

Joint bleeding showed particularly marked improvement. Target joint bleeding decreased from a mean ABR of 3.3 to 0 in the pediatric HAVEN 2 trial. In the Shima study, joint bleeding rates fell from 27.4 to 4.3 in the low-dose cohort, and from 15.2 and 9.1 to 0.0 in the higher-dose cohorts. More than 90% of patients in the Borhany study experienced reduced joint bleeding to 2.4%.

Both systematic reviews quantified the treatment effect across multiple studies. Muniz et al. found a standard mean difference of -1.7 (95% CI -2.4 to -0.9, p<0.00001) for ABR in patients with inhibitors, while Prudente et al. reported a standard mean difference of -1.58 (95% CI -2.50 to -0.66, p=0.0008), though both noted moderate to substantial heterogeneity.

Breakthrough bleeding episodes occurred but were infrequent. In HAVEN 2, breakthrough bleeds were mostly traumatic. The Levy-Mendelovich study documented 31 breakthrough bleeding episodes across 22 of 51 participants over a median 3.3-year follow-up. The HAVEN 1 trial noted that breakthrough bleeding episodes were associated with high cumulative doses of activated prothrombin complex concentrate.

### Safety and tolerability

Emicizumab demonstrated a favorable safety profile across studies, with most adverse events being mild and non-serious.

| Study | Most Frequent Adverse Events | Serious Adverse Events | Thrombotic Events | Injection Site Reactions | Antidrug Antibodies |
|---|---|---|---|---|---|
| J. Oldenburg et al., 2017 | Injection-site reactions (15%) | Thrombotic microangiopathy (2 participants)<br>Thrombosis (2 participants) | Associated with high-dose aPCC | 15% | Not detected (but 2 had declining concentrations) |
| Sheikh Bilal Ahmad et al., 2025 | One non-significant AE | Not mentioned | Not mentioned | Not mentioned | Not mentioned |
| G. Young et al., 2019 | Nasopharyngitis<br>Injection-site reactions | None mentioned | No thrombotic events occurred | Common | 4 developed ADAs (2 with neutralizing potential) |
| R. Muniz et al., 2023 | Injection site reaction | Not mentioned | Not mentioned | Most frequent | Not mentioned |
| M. Shima et al., 2016 | Nasopharyngitis (≥15%) | None reported | None reported | Mild (erythema, rash, pruritus, discomfort) | None developed |
| Caroline Wall et al., 1971 | Cutaneous reactions (3.6%)<br>Headaches (1.4%)<br>Nausea (2.8%)<br>Arthralgia (1.4%) | 3 arterial thrombotic events (2 possibly drug-related) | 3 arterial thrombotic events | Not mentioned | Not mentioned |
| G. Giuffrida et al., 2021 | None occurred | None occurred | None occurred | Not mentioned | Not mentioned |
| Tiago Paiva Prudente et al., 2024 | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Not mentioned |
| M. Borhany et al., 2024 | Well tolerated | Not mentioned | Not mentioned | Not mentioned | Not mentioned |
| Sarina Levy-Mendelovich et al., 2023 | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Not mentioned |

Injection site reactions were the most consistently reported adverse event, occurring in 15% of participants in HAVEN 1, as a common event in HAVEN 2, and as the most frequent adverse event in the Muniz systematic review. These reactions were generally mild, consisting of erythema, rash, pruritus, and discomfort. Only one patient in the Shima study discontinued treatment due to injection-site erythema. The UK registry reported cutaneous reactions in 3.6% of patients.

Other common non-serious adverse events included nasopharyngitis, reported in at least 15% of patients in the Shima study and as a frequent event in HAVEN 2. The UK registry also reported headaches (1.4%), nausea (2.8%), and arthralgia (1.4%), which were generally non-severe and limited to early treatment.

Thrombotic events were rare but serious. HAVEN 1 reported thrombotic microangiopathy and thrombosis in 2 participants each, associated with multiple infusions of activated prothrombin complex concentrate for breakthrough bleeding. The UK registry documented 3 arterial thrombotic events, with 2 possibly drug-related. No thrombotic events occurred in HAVEN 2, the Shima study, or the Giuffrida single-center experience.

Antidrug antibody (ADA) development was uncommon. HAVEN 1 detected no ADAs, though 2 participants showed declining emicizumab concentrations suggesting potential antibodies. In HAVEN 2, 4 participants developed ADAs, with 2 having neutralizing potential. One of these participants experienced loss of efficacy and discontinued treatment, while another had decreased plasma concentrations but remained on study without breakthrough bleeding. ADAs without neutralizing potential did not affect efficacy. No ADAs developed during the Shima study.

Treatment discontinuation rates were low. In HAVEN 2, 87% of participants completed 52 weeks of treatment, with discontinuations due to switching to commercial emicizumab or lack of efficacy. No participants discontinued due to adverse events in the Borhany study, and the Giuffrida study reported no adverse events requiring discontinuation.

### Quality of life outcomes

Quality of life improved substantially with emicizumab prophylaxis in studies that measured patient-reported outcomes.

| Study | Instruments Used | Key Findings |
|---|---|---|
| J. Oldenburg et al., 2017 | Haem-A-QoL<br>EQ-5D-5L | Significant improvements in Haem-A-QoL and EQ-5D-5L scores at week 25 |
| Sheikh Bilal Ahmad et al., 2025 | Not mentioned | Not mentioned |
| G. Young et al., 2019 | Haemo-QoL-SF<br>Inhib-QoL | Week 25 physical health domain score change from baseline: 21.1<br>Reduced days missed from school/daycare: baseline 0.41 to 0.25 at week 13<br>Improved caregiver-reported quality of life |
| R. Muniz et al., 2023 | Not mentioned | Not mentioned |
| M. Shima et al., 2016 | Not mentioned | Not mentioned |
| Caroline Wall et al., 1971 | Haemtrack patient-reported data | Not mentioned |
| G. Giuffrida et al., 2021 | HAL v 2.0<br>pedHAL v 2.0 | Significant improvement in quality of life scores after 6 months |
| Tiago Paiva Prudente et al., 2024 | Not mentioned | Not mentioned |
| M. Borhany et al., 2024 | EQ-5D-5L | 52.6% reduction in pain/discomfort<br>66.6% improvement in self-care<br>58.6% improvement in anxiety/depression<br>Enhanced independence in daily activities |
| Sarina Levy-Mendelovich et al., 2023 | Not mentioned | Not mentioned |

HAVEN 1 demonstrated significant improvements in both disease-specific (Haem-A-QoL) and generic (EQ-5D-5L) quality of life measures at week 25. The pediatric HAVEN 2 trial showed near-maximal improvements in the Haemophilia-Quality of Life Short Form, with a clinically meaningful change of 21.1 points in the physical health domain at week 25. The trial also documented improved caregiver-reported quality of life using the Adapted Health-Related Quality of Life in Haemophilia Patients with Inhibitors questionnaire.

Impact on daily functioning was substantial. School and daycare attendance improved in HAVEN 2, with the proportion of days missed decreasing from a baseline mean of 0.41 to 0.25 at week 13. The Borhany study reported comprehensive improvements across multiple EQ-5D-5L domains: 52.6% reduction in pain/discomfort, 66.6% improvement in self-care, 58.6% improvement in anxiety/depression, and enhanced independence in daily activities. The Giuffrida single-center study found significant improvement in HAL scores after 6 months of emicizumab prophylaxis.

### Synthesis

The evidence converges on emicizumab’s substantial efficacy in reducing bleeding in hemophilia A patients with FVIII inhibitors, though apparent heterogeneity in bleeding rates requires careful interpretation.

#### Explaining Heterogeneity in Bleeding Outcomes

Annualized bleeding rates on emicizumab ranged from 0.0 to 4.4 events per year across studies. This variation reflects predictable differences in study populations and treatment intensity rather than inconsistent drug efficacy. Studies with the lowest bleeding rates (0.0-0.4 events/year) enrolled patients who had previously received prophylactic bypassing agents or had longer observation periods allowing regression to stable state. In contrast, the HAVEN 1 trial’s higher rate of 2.9 events/year included patients transitioning from episodic treatment (group A) or no prophylaxis (group B), representing a more bleeding-prone baseline population.

Dose-response relationships were evident in the Shima dose-escalation study, where higher doses (1.0-3.0 mg/kg weekly) achieved zero joint bleeding, while the lowest dose (0.3 mg/kg) reduced but did not eliminate bleeding (ABR 4.4). The HAVEN 2 trial’s exploration of dosing frequency showed weekly and every-2-week regimens achieved similarly low bleeding rates (0.3 and 0.2 events/year), while the every-4-week regimen had modestly higher rates (2.2 events/year), suggesting diminishing efficacy at extended dosing intervals.

#### Population-Specific Contexts

Age did not substantially affect efficacy. The pediatric HAVEN 2 trial (patients <12 years) achieved a 99% reduction in bleeding versus bypassing agent prophylaxis, comparable to the 79-89% reductions seen in predominantly adult populations. However, the pediatric population showed particularly marked improvement in school attendance, reflecting the unique burden of hemophilia in this developmental stage.

Prior immune tolerance induction (ITI) status created distinct patient subgroups in the Levy-Mendelovich study. Among patients with successful ITI who were then exposed to FVIII during emicizumab prophylaxis, inhibitor levels remained zero, indicating successful tolerance maintenance. In contrast, patients who had failed ITI showed transient anamnestic responses following FVIII exposures, demonstrating that emicizumab does not restore immune tolerance but provides effective prophylaxis independent of tolerance status.

#### Methodological Quality Considerations

The systematic reviews by Muniz et al. and Prudente et al. reported moderate to substantial heterogeneity (I²=68.4%), which they attributed to differences in study populations and previous treatments. Both reviews weighted the large multicenter HAVEN trials most heavily, showing standard mean differences of -1.58 to -1.7 favoring emicizumab. Smaller observational studies contributed to heterogeneity but consistently showed bleeding reductions, supporting the robustness of the effect across settings.

The two thrombotic microangiopathy events in HAVEN 1 occurred specifically in patients receiving high cumulative doses of activated prothrombin complex concentrate for breakthrough bleeding, not in patients receiving emicizumab alone. The UK registry’s three arterial thrombotic events occurred in a real-world cohort with longer follow-up (median 42 months) and potentially more comorbidities than controlled trials, illustrating how safety profiles differ between efficacy trials and effectiveness studies.

#### Conclusions for Specific Contexts

For hemophilia A patients with FVIII inhibitors receiving emicizumab at standard doses (1.5 mg/kg weekly or equivalent every-2-week dosing), bleeding reductions of 79-99% can be expected compared to previous prophylaxis or episodic treatment, with 63-88% achieving zero treated bleeds. Joint bleeding shows particularly marked improvement, translating to improved joint health scores and quality of life.

In patients requiring concurrent bypassing agents for breakthrough bleeds, activated prothrombin complex concentrate should be used cautiously given the thrombotic risk, while recombinant FVIIa appears safer. For patients who have achieved successful ITI, occasional FVIII exposure during emicizumab prophylaxis does not appear to disrupt tolerance, whereas those with failed or deferred ITI may develop transient anamnestic responses.

The development of neutralizing antidrug antibodies, though rare (2 of 88 patients in HAVEN 2), can result in loss of efficacy, warranting monitoring in patients with breakthrough bleeding patterns. Extended dosing intervals beyond 2 weeks may result in higher bleeding rates, though individual variation suggests some patients may tolerate less frequent dosing.

## References

[J. Oldenburg, et al. (2017). Emicizumab Prophylaxis in Hemophilia A with Inhibitors. New England Journal of Medicine](/content/review/5abe4b39-3fe0-48aa-a056-137d1b910897/source/ss-5398937/index.html)

[Sheikh Bilal Ahmad, et al. (2025). A retrospective single-center study on the effectiveness and tolerability of emicizumab in patients with hemophilia a with and without inhibitors. Expert Review of Hematology](/content/review/5abe4b39-3fe0-48aa-a056-137d1b910897/source/ss-276644772/index.html)

[G. Young, et al. (2019). A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood](/content/review/5abe4b39-3fe0-48aa-a056-137d1b910897/source/ss-207947772/index.html)

[R. Muniz, et al. (2023). Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis. Expert Review of Hematology](/content/review/5abe4b39-3fe0-48aa-a056-137d1b910897/source/ss-266158217/index.html)

[M. Shima, et al. (2016). Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. New England Journal of Medicine](/content/review/5abe4b39-3fe0-48aa-a056-137d1b910897/source/ss-205099251/index.html)

[Caroline Wall, et al. (1971). Prophylaxis in haemophilia. The Lancet](/content/review/5abe4b39-3fe0-48aa-a056-137d1b910897/source/ss-5194076/index.html)

[G. Giuffrida, et al. (2021). Use of Emicizumab in Patients with Hemophilia A with and without Inhibitors: A Single Center Experience. Blood](/content/review/5abe4b39-3fe0-48aa-a056-137d1b910897/source/ss-244534428/index.html)

[Tiago Paiva Prudente, et al. (2024). Emicizumab prophylaxis in people with hemophilia A and inhibitors: a systematic review and meta-analysis. Sao Paulo medical journal = Revista paulista de medicina](/content/review/5abe4b39-3fe0-48aa-a056-137d1b910897/source/ss-269736921/index.html)

[M. Borhany, et al. (2024). Emicizumab Prophylaxis in Patients with Severe Hemophilia A: Insights from A Resource Limited Country. Clinical and applied thrombosis/hemostasis](/content/review/5abe4b39-3fe0-48aa-a056-137d1b910897/source/ss-266741008/index.html)

[Sarina Levy-Mendelovich, et al. (2023). Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes. Research and Practice in Thrombosis and Haemostasis](/content/review/5abe4b39-3fe0-48aa-a056-137d1b910897/source/ss-259477905/index.html)